Cognitive Impairment Disorders Drug Development Pipeline Review, 2018
Summary
This report provides an overview of the pipeline landscape for cognitive impairment disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cognitive impairment associated with schizophrenia (CIAS), dementia, mild cognitive impairment and Alzheimer's disease, and features dormant and discontinued products.
These disorders are associated with impairments in cognitive abilities such as learning, memory and perception. Due to the complex and highly sophisticated nature of the central nervous system (CNS), the pathophysiology of these disorders is not well understood and treatment options remain limited. Currently, marketed drugs act by slowing disease progression or treating symptoms.
Worldwide, the burden of cognitive impairment disorders will increase significantly in the coming decades due to aging populations. Consequently, there is a strong need to develop new therapies that effectively treat symptoms and target underlying mechanisms of disease.
Scope
- Which companies are the most active within the pipeline for cognitive impairment disorders?
- Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened within this field?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Cognitive Impairment Disorders Drug Development Pipeline Review, 2018
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 12
2.1 Cognitive Impairment Disorders Report Coverage 12
2.2 Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 12
2.3 Dementia - Overview 12
2.4 Mild Cognitive Impairment - Overview 12
2.5 Alzheimer's Disease - Overview 12
3 Therapeutics Development 13
3.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 13
3.2 Dementia 18
3.3 Mild Cognitive Impairment 30
3.4 Alzheimer's Disease 36
4 Therapeutics Assessment 90
4.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 90
4.2 Dementia 97
4.3 Mild Cognitive Impairment 108
4.4 Alzheimer's Disease 116
5 Companies Involved in Therapeutics Development 140
5.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 140
5.2 Dementia 148
5.3 Mild Cognitive Impairment 173
5.4 Alzheimer's Disease 182
6 Dormant Projects 286
6.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 286
6.2 Dementia 288
6.3 Mild Cognitive Impairment 292
6.4 Alzheimer's Disease 294
7 Discontinued Products 329
7.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 329
7.2 Dementia 330
7.3 Mild Cognitive Impairment 331
7.4 Alzheimer's Disease 332
8 Product Development Milestones 338
8.1 Cognitive Impairment Associated With Schizophrenia (CIAS) 338
8.2 Dementia 339
8.3 Mild Cognitive Impairment 350
8.4 Alzheimer's Disease 357
9 Appendix 372
9.1 Methodology 372
9.2 Coverage 372
9.3 Secondary Research 372
9.4 Primary Research 372
9.5 Expert Panel Validation 372
9.6 Contact Us 372
9.7 Disclaimer 372
1.1 List of Tables
Table 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) 14
Table 2: Number of Products under Development by Companies, Cognitive Impairment Associated With Schizophrenia (CIAS) 16
Table 3: Products under Development by Companies Cognitive Impairment Associated With Schizophrenia (CIAS) 17
Table 4: Number of Products under Development for Dementia 19
Table 5: Number of Products under Development by Companies, Dementia 21
Table 6: Number of Products under Development by Universities/Institutes, Dementia 23
Table 7: Products under Development by Companies, Dementia 24
Table 8: Products under Development by Universities/Institutes, Dementia 30
Table 9: Number of Products under Development for Mild Cognitive Impairment 31
Table 10: Number of Products under Development by Companies, Mild Cognitive Impairment 33
Table 11: Number of Products under Development by Universities/Institutes, Mild Cognitive Impairment 34
Table 12: Products under Development by Companies, Mild Cognitive Impairment 35
Table 13: Products under Development by Universities/Institutes, Mild Cognitive Impairment 37
Table 14: Number of Products under Development for Alzheimer's Disease 38
Table 15: Number of Products under Development by Companies, Alzheimer's Disease 40
Table 16: Number of Products under Development by Universities/Institutes, Alzheimer's Disease 53
Table 17: Products under Development by Companies, Alzheimer's Disease 57
Table 18: Products under Development by Universities/Institutes, Alzheimer's Disease 82
Table 19: Number of Products by Stage and Target, Cognitive Impairment Associated With Schizophrenia (CIAS) 92
Table 20: Number of Products by Stage and Mechanism of Action, Cognitive Impairment Associated With Schizophrenia (CIAS) 94
Table 21: Number of Products by Stage and Route of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS) 96
Table 22: Number of Products by Stage and Molecule Type, Cognitive Impairment Associated With Schizophrenia (CIAS) 98
Table 23: Number of Products by Stage and Target, Dementia 100
Table 24: Number of Products by Stage and Mechanism of Action, Dementia 104
Table 25: Number of Products by Stage and Route of Administration, Dementia 107
Table 26: Number of Products by Stage and Molecule Type, Dementia 109
Table 27: Number of Products by Stage and Target, Mild Cognitive Impairment 111
Table 28: Number of Products by Stage and Mechanism of Action, Mild Cognitive Impairment 113
Table 29: Number of Products by Stage and Route of Administration, Mild Cognitive Impairment 115
Table 30: Number of Products by Stage and Molecule Type, Mild Cognitive Impairment 117
Table 31: Number of Products by Stage and Target, Alzheimer's Disease 119
Table 32: Number of Products by Stage and Mechanism of Action, Alzheimer's Disease 128
Table 33: Number of Products by Stage and Route of Administration, Alzheimer's Disease 138
Table 34: Number of Products by Stage and Molecule Type, Alzheimer's Disease 140
Table 35: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc 141
Table 36: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc 141
Table 37: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Co 142
Table 38: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Cadent Therapeutics 142
Table 39: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd 143
Table 40: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Co 143
Table 41: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd 144
Table 42: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck AS 144
Table 43: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Heptares Therapeutics Ltd 145
Table 44: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies Inc 145
Table 45: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos SL 146
Table 46: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc 146
Table 47: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sage Therapeutics Inc 147
Table 48: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB 147
Table 49: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL 148
Table 50: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Co Ltd 148
Table 51: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc 149
Table 52: Dementia - Pipeline by Acadia Pharmaceuticals Inc 149
Table 53: Dementia - Pipeline by Accera Inc 150
Table 54: Dementia - Pipeline by Acorda Therapeutics Inc 150
Table 55: Dementia - Pipeline by Actinogen Medical Ltd 151
Table 56: Dementia - Pipeline by Adamas Pharmaceuticals Inc 151
Table 57: Dementia - Pipeline by AgeneBio Inc 152
Table 58: Dementia - Pipeline by Alector LLC 152
Table 59: Dementia - Pipeline by Allergan Plc 153
Table 60: Dementia - Pipeline by Anavex Life Sciences Corp 153
Table 61: Dementia - Pipeline by Asceneuron SA 154
Table 62: Dementia - Pipeline by Axon Neuroscience SE 154
Table 63: Dementia - Pipeline by Axovant Sciences Ltd 155
1.2 List of Figures
Figure 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS) 14
Figure 2: Number of Products under Development by Companies, Cognitive Impairment Associated With Schizophrenia (CIAS) 15
Figure 3: Number of Products under Development for Dementia 19
Figure 4: Number of Products under Development by Companies, Dementia 20
Figure 5: Number of Products under Development by Universities/Institutes, Dementia 23
Figure 6: Number of Products under Development for Mild Cognitive Impairment 31
Figure 7: Number of Products under Development by Companies, Mild Cognitive Impairment 32
Figure 8: Number of Products under Development by Universities/Institutes, Mild Cognitive Impairment 34
Figure 9: Number of Products under Development for Alzheimer's Disease 37
Figure 10: Number of Products under Development by Companies, Alzheimer's Disease 39
Figure 11: Number of Products under Development by Universities/Institutes, Alzheimer's Disease 53
Figure 12: Number of Products by Top 10 Targets, Cognitive Impairment Associated With Schizophrenia (CIAS) 91
Figure 13: Number of Products by Stage and Top 10 Targets, Cognitive Impairment Associated With Schizophrenia (CIAS) 91
Figure 14: Number of Products by Top 10 Mechanism of Actions, Cognitive Impairment Associated With Schizophrenia (CIAS) 93
Figure 15: Number of Products by Stage and Top 10 Mechanism of Actions, Cognitive Impairment Associated With Schizophrenia (CIAS) 93
Figure 16: Number of Products by Routes of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS) 95
Figure 17: Number of Products by Stage and Routes of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS) 95
Figure 18: Number of Products by Molecule Types, Cognitive Impairment Associated With Schizophrenia (CIAS) 97
Figure 19: Number of Products by Stage and Molecule Types, Cognitive Impairment Associated With Schizophrenia (CIAS) 97
Figure 20: Number of Products by Top 10 Targets, Dementia 98
Figure 21: Number of Products by Stage and Top 10 Targets, Dementia 99
Figure 22: Number of Products by Top 10 Mechanism of Actions, Dementia 103
Figure 23: Number of Products by Stage and Top 10 Mechanism of Actions, Dementia 103
Figure 24: Number of Products by Top 10 Routes of Administration, Dementia 106
Figure 25: Number of Products by Stage and Top 10 Routes of Administration, Dementia 106
Figure 26: Number of Products by Top 10 Molecule Types, Dementia 108
Figure 27: Number of Products by Stage and Top 10 Molecule Types, Dementia 108
Figure 28: Number of Products by Top 10 Targets, Mild Cognitive Impairment 109
Figure 29: Number of Products by Stage and Top 10 Targets, Mild Cognitive Impairment 110
Figure 30: Number of Products by Top 10 Mechanism of Actions, Mild Cognitive Impairment 112
Figure 31: Number of Products by Stage and Top 10 Mechanism of Actions, Mild Cognitive Impairment 112
Figure 32: Number of Products by Routes of Administration, Mild Cognitive Impairment 114
Figure 33: Number of Products by Stage and Routes of Administration, Mild Cognitive Impairment 114
Figure 34: Number of Products by Molecule Types, Mild Cognitive Impairment 116
Figure 35: Number of Products by Stage and Molecule Types, Mild Cognitive Impairment 116
Figure 36: Number of Products by Top 10 Targets, Alzheimer's Disease 117
Figure 37: Number of Products by Stage and Top 10 Targets, Alzheimer's Disease 118
Figure 38: Number of Products by Top 10 Mechanism of Actions, Alzheimer's Disease 127
Figure 39: Number of Products by Stage and Top 10 Mechanism of Actions, Alzheimer's Disease 127
Figure 40: Number of Products by Top 10 Routes of Administration, Alzheimer's Disease 137
Figure 41: Number of Products by Stage and Top 10 Routes of Administration, Alzheimer's Disease 137
Figure 42: Number of Products by Top 10 Molecule Types, Alzheimer's Disease 139
Figure 43: Number of Products by Stage and Top 10 Molecule Types, Alzheimer's Disease 139
Global Antioxidant Vitamins Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 100
The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
Global Clavulanate Potassium Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 86
The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030.
North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
Global Amoxicillin Sodium Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 84
The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030.
North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
Global Melatonin Supplements Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 106
The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 93
The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
Global Sleeping Pills Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 94
The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
Global Zinc Oral Drops Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
Global Zinc Drops Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
Global Anti-Infectives Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 78
The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
